Sichuan Biokin Pharmaceutical Co.,Ltd. in 1 story
The narratives 688506.SS currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
688506.SS in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Biokin demonstrated the value of Chinese ADC innovation through Bristol Myers Squibb's multibillion-dollar licensing agreement for the bispecific ADC izalontamab brengitecan.
Bear side
0 storiesNo bear-side stories for 688506.SS yet.